Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Completed 30Terminated 4Recruiting 2Withdrawn 1Unknown 1Active not recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4Gynecologic 2Genitourinary 1Dermatologic 1Breast 1

Conditions

Ovarian Neoplasms 19Small Cell Lung Carcinoma 9Carcinoma, Ovarian Epithelial 8Fallopian Tube Neoplasms 7Recurrence 6Brain Neoplasms 5Neuroblastoma 4Neoplasms 4Lung Neoplasms 4Medulloblastoma 3Glioma 3Central Nervous System Neoplasms 3Uterine Cervical Neoplasms 2Rhabdoid Tumor 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasm Metastasis 2Meningeal Carcinomatosis 2Familial ependymoma 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Astrocytoma 2Unspecified Childhood Solid Tumor, Protocol Specific 1Unspecified Adult Solid Tumor, Protocol Specific 1Triple Negative Breast Neoplasms 1Sarcoma 1Rhabdomyosarcoma 1Retinoblastoma 1Optic Nerve Glioma 1Oligodendroglioma 1

Interventions

Carboplatin 49Pemetrexed 38Cisplatin 34Radiotherapy 32Docetaxel 31Gemcitabine 25Paclitaxel 24Nivolumab 18pembrolizumab 15Etoposide 15Radiosurgery 13Erlotinib Hydrochloride 11Bevacizumab 11Magnetic Resonance Spectroscopy 10Vinorelbine 9Radiation 9Cyclophosphamide 7durvalumab 6Gefitinib 6Fluorodeoxyglucose F18 6Celecoxib 6atezolizumab 5Oxaliplatin 5Irinotecan 5Immunoglobulin G 5Drug Therapy 5Disulfides 5Dexamethasone 5Chemotherapy, Adjuvant 5vandetanib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Terminated × Lung Neoplasms × Topotecan × Clear all
NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

M.D. Anderson Cancer Center

Phase 1 Terminated
221 enrolled
BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT02649673 2023-12-05

LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies

SCRI Development Innovations, LLC

Phase 1 Terminated
34 enrolled
GynecologicThoracic

Lung Neoplasms, Ovarian Neoplasms, Small Cell Lung Carcinoma

NCT02963090 2023-02-15

Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer

Alliance Foundation Trials, LLC.

Phase 2 Terminated
9 enrolled 11 charts
Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

NCT00087048 2016-03-22

Topotecan in Treating Patients With Recurrent Extensive-Stage Small Cell Lung Cancer

Case Comprehensive Cancer Center

Phase 2 Terminated
1 enrolled
Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡